63 related articles for article (PubMed ID: 2624596)
1. [Determination of the release of drugs from transdermal therapeutic systems. Presentation of a new release system].
Chen LS; Ebel S; Hoffmann U; Osterwald HP
Arzneimittelforschung; 1989 Nov; 39(11A):1494-7. PubMed ID: 2624596
[TBL] [Abstract][Full Text] [Related]
2. [The bioavailability of transdermal therapeutic system of timolol].
Ji XF; Ping QN; Liu GJ; Yu ST
Yao Xue Xue Bao; 1993; 28(8):609-13. PubMed ID: 8285070
[TBL] [Abstract][Full Text] [Related]
3. Release characteristics of anionic drug compounds from liquid crystalline gels. Part II. The effects of ion pairing and buffering on the passive delivery of anionic drugs across non-rate-limiting membranes.
Fitzpatrick D; Corish J
Int J Pharm; 2006 Mar; 311(1-2):139-46. PubMed ID: 16426777
[TBL] [Abstract][Full Text] [Related]
4. Application of sucrose fatty acid esters in transdermal therapeutic systems.
Csóka G; Marton S; Zelko R; Otomo N; Antal I
Eur J Pharm Biopharm; 2007 Feb; 65(2):233-7. PubMed ID: 16963242
[TBL] [Abstract][Full Text] [Related]
5. Development of transdermal system containing nicotine by using sustained release dosage design.
Tirnaksiz F; Yuce Z
Farmaco; 2005 Sep; 60(9):763-70. PubMed ID: 16019001
[TBL] [Abstract][Full Text] [Related]
6. Controlled release of atenolol from the ethylene-vinyl acetate matrix.
Kim J; Shin SC
Int J Pharm; 2004 Apr; 273(1-2):23-7. PubMed ID: 15010126
[TBL] [Abstract][Full Text] [Related]
7. Release characteristics of anionic drug compounds from liquid crystalline gels I: Passive release across non-rate-limiting membranes.
Fitzpatrick D; Corish J
Int J Pharm; 2005 Sep; 301(1-2):226-36. PubMed ID: 16084043
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of carboxymethyl guar films for the formulation of transdermal therapeutic systems.
Narasimha Murthy S; Hiremath SR; Paranjothy KL
Int J Pharm; 2004 Mar; 272(1-2):11-8. PubMed ID: 15019064
[TBL] [Abstract][Full Text] [Related]
9. Cultured skin loaded with tetracycline HCl and chloramphenicol as dermal delivery system: mathematical evaluation of the cultured skin containing antibiotics.
Hada N; Hasegawa T; Takahashi H; Ishibashi T; Sugibayashi K
J Control Release; 2005 Nov; 108(2-3):341-50. PubMed ID: 16226333
[TBL] [Abstract][Full Text] [Related]
10. Determination of diclofenac released from suppositories using UV spectrophotometry, spectra derivative spectrophotometry and HPLC.
Sznitowska M; Stokrocka M
Acta Pol Pharm; 2007; 64(5):401-5. PubMed ID: 18540158
[TBL] [Abstract][Full Text] [Related]
11. Mathematical modelling of the release of drug from porous, nonswelling transdermal drug-delivery devices.
Lee AJ; King JR; Hibberd S
IMA J Math Appl Med Biol; 1998 Jun; 15(2):135-63. PubMed ID: 9661281
[TBL] [Abstract][Full Text] [Related]
12. Transdermal self-permeation enhancement of ibuprofen.
Al-Saidan SM
J Control Release; 2004 Nov; 100(2):199-209. PubMed ID: 15544868
[TBL] [Abstract][Full Text] [Related]
13. Effect of polyoxyethylene glycols (PEG) on properties of the matrix model of transdermal therapeutic system (TTS) with testosterone.
Cichon R; Janicki S
Pharmazie; 1991 Oct; 46(10):719-23. PubMed ID: 1803388
[TBL] [Abstract][Full Text] [Related]
14. Influence of the formulation on the in vitro transdermal penetration of sodium diclofenac. Evaluation of the topical and systemic anti-inflammatory activity in the rat.
Calpena AC; Escribano E; San Martin H; Lauroba J; Obach R; Domenech J
Arzneimittelforschung; 1999 Dec; 49(12):1012-7. PubMed ID: 10635447
[TBL] [Abstract][Full Text] [Related]
15. Poly(2-hydroxy-3-phenoxypropylacrylate, 4-hydroxybutyl acrylate, dibutyl maleate) membrane controlled clonidine zero-order release.
Zhan X; Chen S; Tang G; Mao Z
Eur J Pharm Biopharm; 2007 Jun; 66(3):429-34. PubMed ID: 17196806
[TBL] [Abstract][Full Text] [Related]
16. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow.
Ali M; Horikawa S; Venkatesh S; Saha J; Hong JW; Byrne ME
J Control Release; 2007 Dec; 124(3):154-62. PubMed ID: 17964678
[TBL] [Abstract][Full Text] [Related]
17. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs.
Prabakaran D; Singh P; Jaganathan KS; Vyas SP
J Control Release; 2004 Mar; 95(2):239-48. PubMed ID: 14980772
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies on the transdermal formulation containing pentoxifylline microspheres with poly-L-lactide.
Ozsoy Y; Caybaşi P; Terzioğlu N; Ozkirimli S; Tunçel T
Boll Chim Farm; 2002; 141(1):29-32. PubMed ID: 12064054
[TBL] [Abstract][Full Text] [Related]
19. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems.
Sintov AC; Botner S
Int J Pharm; 2006 Mar; 311(1-2):55-62. PubMed ID: 16431047
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects.
Raz I; Hussein Z; Samara E; Ben-David J
Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):246-8. PubMed ID: 3410601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
